Browse the evidence

Unimolecular dual-agonists targeting GLP-1 and GIP receptors (e.g., tirzepatide) provide superior glycemic control and weight loss compared to GLP-1 receptor agonists alone by leveraging additive insulinotropic effects and distinct metabolic pathways.

If you have Type 2 Diabetes and struggle with weight, dual-agonist medications (like tirzepatide) may offer better blood sugar control and weight loss than older GLP-1 drugs. These medications work by mimicking gut hormones to boost insulin, reduce appetite, and increase energy expenditure. While they are injections and may cause temporary nausea, the clinical benefits for metabolic health are significant. Consult your doctor to see if this advanced therapy is appropriate for your specific health profile.

Obesity is associated with decreased prefrontal cortex activity and decreases in goal-directed decision-making, which influences food intake.

Recognize that obesity involves physiological changes in the brain, specifically decreased prefrontal cortex activity and goal-directed decision-making. This means relying solely on willpower is biologically harder for individuals with obesity, and strategies should account for these neural differences (e.g., environmental changes, behavioral training).

Lifestyle interventions (diet and physical activity) improve cardiometabolic risk through mechanisms independent of weight loss, primarily by reducing visceral and ectopic fat and improving metabolic markers.

Do not focus on the scale. Focus on improving diet quality and increasing physical activity. These actions will reduce visceral fat and improve metabolic markers (blood pressure, lipids, glucose) even if your total weight doesn't change much. This is the most effective way to reduce cardiovascular risk.

GLP-1 receptor agonists (GLP-1RAs) effectively manage type 2 diabetes and obesity by mimicking endogenous GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, and promote satiety through delayed gastric emptying and hypothalamic signaling.

GLP-1 receptor agonists are a proven treatment for Type 2 Diabetes and obesity. They work by mimicking a natural hormone to help your pancreas release insulin when needed, stop the release of sugar-storing hormones, and make you feel full faster. This leads to better blood sugar control and weight loss. While they are effective, they require injections, which can be a barrier for some patients.

GLP-1 receptor agonists induce significant fat mass loss with a non-significant or significantly smaller reduction in muscle mass, resulting in muscle mass accounting for less than 20% of total weight loss.

If you are taking a GLP-1 medication like Ozempic or Wegovy, your body is prioritizing fat loss over muscle loss. While you may lose a small amount of muscle, it is a minor fraction of your total weight loss (under 20%). Focus on maintaining strength through resistance training to preserve the muscle you have, but do not let fear of muscle loss stop you from using effective weight management tools.

Excessive fructose intake disrupts gut microbiota, reduces beneficial butyrate-producing bacteria, and downregulates tight junction proteins (ZO-1, Claudin-1, occludin), leading to increased intestinal permeability, endotoxemia, and obesity.

Excessive fructose, especially from syrup, damages your gut lining by reducing beneficial bacteria and tight junction proteins, leading to 'leaky gut' and inflammation. While moderate natural fructose from fruit is likely safe, avoid excessive fructose syrup to protect your gut and weight.

Protein intake in indoor team sports is the macronutrient most likely to meet official recommendations, with roughly 35.7% of studies showing compliance, though non-compliance is split evenly between under- and over-consumption.

You are more likely to hit your protein targets than your carb or energy targets, but you are still at risk of under-eating protein. Ensure you are eating enough protein to support recovery, but be aware that half of athletes in these studies under-consume it.

Performing bariatric surgery during the pre-diabetic or early diabetic stages significantly reduces the incidence of type 2 diabetes and promotes remission, whereas delaying surgery until advanced stages with established complications yields minimal metabolic benefit and higher mortality risk.

If you have obesity and type 2 diabetes (or pre-diabetes), do not wait until your condition is severe or you have complications like kidney or eye damage. Seek bariatric surgery evaluation early. The evidence shows that operating while your diabetes is new or in the pre-diabetic stage offers the highest chance of reversing the disease and preventing long-term damage, whereas waiting until the disease is advanced often fails to provide survival or health benefits.

Resistance-trained individuals achieve similar quadriceps muscle hypertrophy after eight weeks of resistance training when terminating sets with 1-2 repetitions in reserve (RIR) compared to terminating sets at momentary muscular failure.

If you are experienced with resistance training, you do not need to train to absolute failure on every set to build muscle. Stopping your sets with 1-2 reps left in the tank (RIR) produces the same muscle growth as going to failure over an 8-week period. This approach likely allows you to recover faster and maintain better form, as failure training induces significantly higher acute fatigue and repetition loss.

Sarcopenic obesity, characterized by increased fat stores and decreased muscle mass, is a distinct and dangerous body composition status in the elderly that is often masked by net weight loss.

For older adults, weight loss can be dangerous if it involves muscle loss. Focus on maintaining muscle mass through resistance exercise and adequate protein intake, rather than just trying to lose weight, to avoid 'sarcopenic obesity'.

GLP-1 receptor agonists (GLP-1RAs) and dual/triple incretin agonists produce clinically relevant hepatic improvements in patients with metabolic dysfunction-associated steatohepatitis (MASH), including MASH resolution, liver fat reduction, and prevention of fibrosis worsening.

If you have MASH or MASLD, especially with obesity or type 2 diabetes, GLP-1 receptor agonists (like semaglutide or tirzepatide) are a valuable treatment option. They not only help with weight and blood sugar but also directly improve liver health by reducing fat and inflammation. While lifestyle changes remain important, these medications can help achieve the necessary weight loss (7-10%) if you struggle to do so alone. Discuss these options with your gastroenterologist.

Among GLP-1 receptor agonists, tirzepatide induces the greatest reduction in body mass index (BMI), while orforglipron demonstrates the strongest benefit in lowering systolic blood pressure.

Not all GLP-1 drugs are equal for every health goal. If your primary concern is significant weight loss, tirzepatide shows the greatest BMI reduction in this analysis. If high blood pressure is the main issue, orforglipron showed the strongest blood pressure-lowering effect. Consult your doctor to choose the agent that best targets your specific cardiometabolic risks.

GLP-1 receptor agonist therapies significantly reduce C-reactive protein (CRP) levels, with semaglutide showing the most efficacious reduction compared to other agents.

GLP-1 therapies also help reduce systemic inflammation, as measured by C-reactive protein (CRP). Semaglutide was found to be particularly effective at lowering CRP levels, which may contribute to its cardiovascular benefits.

GLP-1 receptor agonists (specifically liraglutide) significantly reduce body weight and improve cardiometabolic risk factors (BMI, fasting plasma glucose, lipid profile) in obese or overweight individuals with psychotic disorders treated with antipsychotic drugs.

For patients with psychotic disorders on antipsychotics who struggle with obesity, GLP-1 receptor agonists (especially liraglutide) are a proven, effective treatment for weight loss and improving metabolic health. They significantly reduce body weight, BMI, and improve blood sugar and lipid levels without increasing the risk of stopping treatment compared to standard care. Liraglutide appears more effective than exenatide for weight loss in this group.

GLP-1 receptor agonists significantly improve lipid profiles (reducing Total Cholesterol and LDL-C, increasing HDL-C) and fasting plasma glucose in obese individuals with psychotic disorders, but do not significantly affect waist circumference, systolic/diastolic blood pressure, or triglycerides.

GLP-1 receptor agonists improve blood sugar and cholesterol levels (lowering bad cholesterol and triglycerides, raising good cholesterol) in patients with psychotic disorders, but they do not significantly lower blood pressure or waist circumference. This makes them valuable for metabolic health, even if blood pressure remains unchanged.

Meeting multiple glycemic criteria (IFG, IGT, and/or elevated HbA1c) for prediabetes significantly increases the risk of progressing to type 2 diabetes compared to meeting only one criterion.

If you have prediabetes, ask your doctor to check all three glycemic markers (fasting glucose, 2-hour post-meal glucose, and HbA1c). Meeting more than one abnormal result means your risk of developing type 2 diabetes is much higher, and you should prioritize intensive lifestyle changes or discuss medication with your provider immediately.

Obesity is a heterogeneous condition where distinct subtypes exist based on metabolic and genetic profiles, necessitating personalized treatment strategies rather than uniform BMI-based approaches.

Stop treating all obesity as the same. Your doctor should look beyond your weight to your metabolic health (blood sugar, lipids) and genetics to determine the best treatment for you, which might include specific medications or lifestyle changes tailored to your body's unique biology.

Storing fat subcutaneously (especially in the hips and thighs) is metabolically favorable compared to storing it viscerally or in the liver, reducing the risk of type 2 diabetes and cardiovascular disease despite higher overall body fat.

Focus on maintaining muscle mass and healthy fat distribution rather than just losing weight. If you have a 'pear' shape (fat stored in hips/thighs), you may have a lower risk of diabetes than someone with a 'apple' shape (visceral fat), even if your BMI is high.

Sarcopenia (defined by low handgrip strength and/or low muscle mass) is associated with a significantly higher long-term risk of developing atrial fibrillation (AF) in Caucasian populations, independent of genetic predisposition and lifestyle factors.

Prioritize resistance training and adequate protein intake to maintain muscle mass and strength, especially if you are female or under 65, as these groups showed a stronger link between muscle loss and heart rhythm issues. Regular assessment of handgrip strength and muscle mass can serve as an early warning system for cardiovascular risk.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior glycemic control and greater weight loss compared to GLP-1 receptor agonists (semaglutide, dulaglutide) and insulin analogs (degludec, glargine) in patients with type 2 diabetes.

If you have Type 2 Diabetes or obesity, Tirzepatide is a once-weekly injection that lowers blood sugar and reduces body weight more effectively than current GLP-1 drugs (like semaglutide) or insulin. It works by mimicking two gut hormones (GIP and GLP-1). Common side effects are gastrointestinal, but they often decrease over time. Consult a doctor to see if you are a candidate.

An intensive lifestyle intervention (ILI) involving caloric restriction and physical activity improves preference-based health-related quality of life (HRQOL) in individuals with type 2 diabetes, but this improvement is statistically significant and clinically relevant primarily in the short term (first year), with long-term effects being small, inconsistent across measurement instruments, and often failing to reach minimally important difference (MID) thresholds.

If you have type 2 diabetes, an intensive lifestyle program focusing on diet and exercise will likely improve how you feel about your health, especially in the first year. However, expect the benefits to plateau and become smaller over time. To maintain any quality of life gains, you must actively work to prevent weight regain, as the study shows that compliance drops and weight is regained after the first year, eroding these benefits.

GLP-1 receptor agonists (e.g., liraglutide) induce weight loss primarily by targeting brainstem circuits (specifically the area postrema) rather than mimicking natural gut signals, as natural GLP-1 levels do not regulate body weight.

GLP-1 drugs work by targeting the brainstem to reduce food intake, not by mimicking natural gut signals. This is a distinct mechanism from natural satiety.

Semaglutide 2.4 mg treatment leads to preferential loss of fat mass over lean body mass, which supports improvements in physical function and walking capacity.

Semaglutide 2.4 mg helps you lose fat mass more than lean body mass, which supports your physical function and walking capacity. This is achieved through once-weekly injections combined with lifestyle changes.

Current GLP-1-based anti-obesity medications (AOMs) achieve profound acute body weight loss (up to 25%) but are associated with significant real-world treatment discontinuation (up to 50%) due to gastrointestinal side effects and lack of lifestyle counseling, necessitating novel formulations with improved tolerability.

While GLP-1 drugs like semaglutide and tirzepatide produce significant weight loss, real-world adherence is a major hurdle due to gastrointestinal side effects. To maximize success, patients should utilize flexible, patient-determined titration schedules rather than fixed rapid escalation, and consider prophylactic anti-emetics if needed, as these strategies improve long-term tolerability and adherence.